Kane Biotech Inc. (KNE.V)
CAD 0.1
(0.0%)
CAD 0.1
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.68 Million CAD | 1.09% |
| 2022 | 5.61 Million CAD | -8.39% |
| 2021 | 6.13 Million CAD | 21.82% |
| 2020 | 5.03 Million CAD | 82.74% |
| 2019 | 2.75 Million CAD | 77.11% |
| 2018 | 1.55 Million CAD | -54.2% |
| 2017 | 3.39 Million CAD | 59.4% |
| 2016 | 2.13 Million CAD | 81.67% |
| 2015 | 1.17 Million CAD | -41.03% |
| 2014 | 1.98 Million CAD | 5.62% |
| 2013 | 1.88 Million CAD | -25.4% |
| 2012 | 2.52 Million CAD | 2.19% |
| 2011 | 2.47 Million CAD | 96.98% |
| 2010 | 1.25 Million CAD | -32.78% |
| 2009 | 1.86 Million CAD | 18.67% |
| 2008 | 1.57 Million CAD | 27.98% |
| 2007 | 1.22 Million CAD | -19.04% |
| 2006 | 1.51 Million CAD | 31.73% |
| 2005 | 1.15 Million CAD | 118.87% |
| 2004 | 526.37 Thousand CAD | -48.0% |
| 2003 | 1.01 Million CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 5.79 Million CAD | 2.07% |
| 2024 Q2 | 4.07 Million CAD | -29.74% |
| 2023 Q4 | 5.68 Million CAD | -5.49% |
| 2023 Q1 | 5.46 Million CAD | -2.75% |
| 2023 Q2 | 5.58 Million CAD | 2.14% |
| 2023 FY | 5.68 Million CAD | 1.09% |
| 2023 Q3 | 6.01 Million CAD | 7.68% |
| 2022 Q2 | 7.41 Million CAD | 30.53% |
| 2022 Q1 | 5.67 Million CAD | -7.42% |
| 2022 Q4 | 5.61 Million CAD | -14.79% |
| 2022 FY | 5.61 Million CAD | -8.39% |
| 2022 Q3 | 6.59 Million CAD | -11.03% |
| 2021 Q3 | 6.54 Million CAD | 14.02% |
| 2021 Q1 | 4.46 Million CAD | -11.39% |
| 2021 FY | 6.13 Million CAD | 21.82% |
| 2021 Q2 | 5.73 Million CAD | 28.56% |
| 2021 Q4 | 6.13 Million CAD | -6.21% |
| 2020 Q3 | 4.88 Million CAD | 83.31% |
| 2020 FY | 5.03 Million CAD | 82.74% |
| 2020 Q2 | 2.66 Million CAD | 5.07% |
| 2020 Q4 | 5.03 Million CAD | 3.05% |
| 2020 Q1 | 2.53 Million CAD | -7.93% |
| 2019 Q3 | 2.1 Million CAD | -26.21% |
| 2019 FY | 2.75 Million CAD | 77.11% |
| 2019 Q4 | 2.75 Million CAD | 30.66% |
| 2019 Q1 | 1.63 Million CAD | 5.38% |
| 2019 Q2 | 2.85 Million CAD | 74.32% |
| 2018 Q3 | 1.56 Million CAD | -9.95% |
| 2018 Q2 | 1.73 Million CAD | -36.12% |
| 2018 Q4 | 1.55 Million CAD | -0.65% |
| 2018 FY | 1.55 Million CAD | -54.2% |
| 2018 Q1 | 2.72 Million CAD | -19.85% |
| 2017 FY | 3.39 Million CAD | 59.4% |
| 2017 Q2 | 1.75 Million CAD | -13.96% |
| 2017 Q4 | 3.39 Million CAD | -14.65% |
| 2017 Q3 | 3.98 Million CAD | 127.3% |
| 2017 Q1 | 2.03 Million CAD | -4.51% |
| 2016 Q1 | 1.42 Million CAD | 21.14% |
| 2016 FY | 2.13 Million CAD | 81.67% |
| 2016 Q4 | 2.13 Million CAD | -21.06% |
| 2016 Q3 | 2.69 Million CAD | -17.25% |
| 2016 Q2 | 3.26 Million CAD | 129.59% |
| 2015 Q1 | 1.61 Million CAD | -18.97% |
| 2015 FY | 1.17 Million CAD | -41.03% |
| 2015 Q3 | 1.22 Million CAD | -6.13% |
| 2015 Q4 | 1.17 Million CAD | -4.48% |
| 2015 Q2 | 1.3 Million CAD | -18.84% |
| 2014 Q3 | 1.25 Million CAD | -8.95% |
| 2014 FY | 1.98 Million CAD | 5.62% |
| 2014 Q1 | 1.87 Million CAD | -0.55% |
| 2014 Q2 | 1.38 Million CAD | -26.19% |
| 2014 Q4 | 1.98 Million CAD | 58.05% |
| 2013 Q1 | 2.06 Million CAD | -18.37% |
| 2013 Q4 | 1.88 Million CAD | 28.79% |
| 2013 Q2 | 1.7 Million CAD | -17.2% |
| 2013 FY | 1.88 Million CAD | -25.4% |
| 2013 Q3 | 1.46 Million CAD | -14.3% |
| 2012 Q4 | 2.52 Million CAD | 69.57% |
| 2012 FY | 2.52 Million CAD | 2.19% |
| 2012 Q1 | 2.15 Million CAD | -12.64% |
| 2012 Q2 | 1.84 Million CAD | -14.38% |
| 2012 Q3 | 1.48 Million CAD | -19.44% |
| 2011 Q1 | 1.12 Million CAD | -10.46% |
| 2011 FY | 2.47 Million CAD | 96.98% |
| 2011 Q2 | 2.95 Million CAD | 162.71% |
| 2011 Q3 | 2.7 Million CAD | -8.29% |
| 2011 Q4 | 2.47 Million CAD | -8.69% |
| 2010 Q4 | 1.25 Million CAD | 4.94% |
| 2010 FY | 1.25 Million CAD | -32.78% |
| 2010 Q3 | 1.19 Million CAD | -15.61% |
| 2010 Q2 | 1.41 Million CAD | -15.49% |
| 2010 Q1 | 1.67 Million CAD | -10.17% |
| 2009 Q1 | 1.33 Million CAD | -15.08% |
| 2009 FY | 1.86 Million CAD | 18.67% |
| 2009 Q4 | 1.86 Million CAD | 42.47% |
| 2009 Q3 | 1.3 Million CAD | -0.71% |
| 2009 Q2 | 1.31 Million CAD | -1.2% |
| 2008 FY | 1.57 Million CAD | 27.98% |
| 2008 Q4 | 1.57 Million CAD | -6.77% |
| 2008 Q3 | 1.68 Million CAD | -21.2% |
| 2008 Q1 | 2.48 Million CAD | 102.09% |
| 2008 Q2 | 2.14 Million CAD | -13.8% |
| 2007 Q4 | 1.22 Million CAD | -11.84% |
| 2007 Q2 | 1.04 Million CAD | -18.26% |
| 2007 Q1 | 1.27 Million CAD | -15.9% |
| 2007 FY | 1.22 Million CAD | -19.04% |
| 2007 Q3 | 1.39 Million CAD | 33.59% |
| 2006 Q3 | 1.84 Million CAD | -9.95% |
| 2006 Q4 | 1.51 Million CAD | -17.75% |
| 2006 Q2 | 2.04 Million CAD | 101.89% |
| 2006 Q1 | 1.01 Million CAD | -11.91% |
| 2006 FY | 1.51 Million CAD | 31.73% |
| 2005 Q2 | 1.59 Million CAD | -11.82% |
| 2005 FY | 1.15 Million CAD | 118.87% |
| 2005 Q1 | 1.81 Million CAD | 244.43% |
| 2005 Q3 | 1.3 Million CAD | -18.07% |
| 2005 Q4 | 1.15 Million CAD | -12.05% |
| 2004 FY | 526.37 Thousand CAD | -48.0% |
| 2004 Q1 | 932.71 Thousand CAD | -7.86% |
| 2004 Q2 | 753.81 Thousand CAD | -19.18% |
| 2004 Q3 | 629.79 Thousand CAD | -16.45% |
| 2004 Q4 | 526.37 Thousand CAD | -16.42% |
| 2003 Q2 | 821.77 Thousand CAD | 0.0% |
| 2003 Q3 | 1.06 Million CAD | 29.68% |
| 2003 Q4 | 1.01 Million CAD | -5.01% |
| 2003 FY | 1.01 Million CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Arch Biopartners Inc. | 1.17 Million CAD | -385.063% |
| Covalon Technologies Ltd. | 24.9 Million CAD | 77.186% |
| Hemostemix Inc. | 313.76 Thousand CAD | -1710.565% |
| Universal Ibogaine Inc. | 6.31 Million CAD | 10.078% |
| MedMira Inc. | 3.65 Million CAD | -55.565% |
| Marvel Biosciences Corp. | 672.38 Thousand CAD | -744.886% |
| NervGen Pharma Corp. | 13.23 Million CAD | 57.08% |
| XORTX Therapeutics Inc. | 7.21 Million CAD | 21.208% |